In order to satiate youth-hungry bald people, scientists are growing human hair cells on mice.
Ernesto Lujan, a biologist and founder of medical startup dNovo, told MIT Technology Review that his company has successfully transplanted human hair stem cells onto a mouse.
The result is a horrifying abomination of all that is good, and proof that science has gone too far.
Safed’s Ziv Medical Center has sent a letter to Health Ministry director Nachman Ash requesting he grant emergency authorization for the anti-COVID drug Amor 18 developed by the Israeli company Amorphical in order to treat patients in moderate to serious condition due to the coronavirus, Channel 2 reported Friday.
In letter to Health Ministry director, Ziv Medical Center points to promising results from Amor 18’s clinical trial, where all patients who received drug went on to recover (drug uses Amorphous Calcium Carbonate: ACC).
Israeli biotech company Amorphical recently published what it says are promising results from the second stage of its Amor 18 clinical study.
-please note: Regeneron helped end the ebola pandemic by ending clinical trials early and getting treatments to patients ASAP.
Clinical trial: https://clinicaltrials.gov/ct2/show/NCT04900337
What is AI, really? Jeff Dean, the head of Google’s AI efforts, explains the underlying technology that enables artificial intelligence to do all sorts of things, from understanding language to diagnosing disease — and presents a roadmap for building better, more responsible systems that have a deeper understanding of the world. (Followed by a Q&A with head of TED Chris Anderson)
Visit http://TED.com to get our entire library of TED Talks, transcripts, translations, personalized talk recommendations and more.
The TED Talks channel features the best talks and performances from the TED Conference, where the world’s leading thinkers and doers give the talk of their lives in 18 minutes (or less). Look for talks on Technology, Entertainment and Design — plus science, business, global issues, the arts and more. You’re welcome to link to or embed these videos, forward them to others and share these ideas with people you know.
Become a TED Member: http://ted.com/membership.
Follow TED on Twitter: http://twitter.com/TEDTalks.
Like TED on Facebook: http://facebook.com/TED
TED’s videos may be used for non-commercial purposes under a Creative Commons License, Attribution–Non Commercial–No Derivatives (or the CC BY – NC – ND 4.0 International) and in accordance with our TED Talks Usage Policy (https://www.ted.com/about/our-organization/our-policies-term…e-policy). For more information on using TED for commercial purposes (e.g. employee learning, in a film or online course), please submit a Media Request at https://media-requests.ted.com
64x Bio comes out of the Harvard Department of Genetics. CEO Lex Rovner and her team — which right now, sits around 10 people — are looking to tackle a key hurdle for major companies: manufacturing cell and gene therapies.
Rovner met Church while getting her PhD at Yale, and went on to do a postdoctoral research fellowship in his lab, and, when talking to folks in the industry, found a massive viral vector manufacturing bottleneck that wasn’t being talked about.
After a seed funding round and the company’s launch in 2020, it made some noise in the industry, particularly as Covid-19 made bottleneck issues more visible. There’s a waitlist to get a vector from manufacturers, and not much of a solution to the problem.
There is nothing inevitable about aging, or about its rate. Californian bristlecone pines are believed to live for 5,000 years, and there are long-lived mammalian creatures as well. Some marine creatures do not display any signs of aging at all, including hydra, jellyfish, planarian worms, and coral. Certain human cells have immortal characteristics too. When a woman gives birth, she produces a baby which is “new”. Her “germline” (reproduction-related) cells produce a child with no signs of age.
These and many other considerations combine with the unreasonable effectiveness of modern AI to lead some people to believe that significant advances in longevity are imminent. These advances probably cannot happen without the active participation of the wider pharmaceutical industry, and the acceptance by policy makers and regulators that aging is a disease, not just an unfortunate and inevitable component of the human condition. There is still considerable reluctance among major pharmaceutical companies to contemplate specific anti-aging therapeutic developments. But there are encouraging signs of this reluctance being challenged, especially at Novartis and AstraZeneca.
Beyond the pharma giants, Mellon reckons there are 255 companies which claim to be specifically targeting aging, of which 35 are listed on stock markets. But he thinks that only a minority of them are genuinely working to tackle aging, as opposed to one of the diseases it causes, like cancer, dementia, or heart disease. He likens the state of the longevity industry today to the internet industry of 20 years ago, when it was still in its dial-up phase, and downloading information (or, heaven forbid, images) was like sucking jelly through a straw. And although longevity will have such a massive impact on all of us that you might expect progress to be expedited, Mellon points out that the internet did not have to go through lengthy and expensive FDA trials at every step.
Autophagy is often likened to the trash management system of the cell. And just as municipal waste services involve collection, transportation and ultimately disposal, so too must the cell’s autophagy system follow a coordinated, multistep process. It first requires cellular refuse to be bagged up inside sack-like structures known as phagophores. These then mature into cargo containers called autophagosomes, which fuse with degradation hubs called lysosomes. Only then do waste products get broken down.
Any part of that cell-cleaning process could go wrong, and they often do as cells age. But if researchers do not fully understand what aspects of autophagy are defective in any particular disease, drugs that modulate the wrong parts of the pathway could do more harm than good. A therapy could, for instance, help the cell to package more trash. “But if your trash compactor isn’t working properly, you’re just going to end up with a room full of trash bags,” says Tim Sargeant, who studies autophagy at the South Australian Health and Medical Research Institute in Adelaide. “That’s one of the dangers here.”
As a result, although some anti-ageing researchers and companies have gone all-in on targeting autophagy, others are more circumspect — especially given the lack of solid evidence in people or even mouse models for many of the proposed interventions.
Cardiovascular disease is the leading cause of death worldwide and bears an immense economic burden. Late-stage heart failure often requires total heart transplantation; however, due to donor shortages and lifelong immunosuppression, alternative cardiac regenerative therapies are in high demand. Human pluripotent stem cells (hPSCs), including human embryonic and induced pluripotent stem cells, have emerged as a viable source of human cardiomyocytes for transplantation. Recent developments in several mammalian models of cardiac injury have provided strong evidence of the therapeutic potential of hPSC-derived cardiomyocytes (hPSC-CM), showing their ability to electromechanically integrate with host cardiac tissue and promote functional recovery. In this review, we will discuss recent developments in hPSC-CM differentiation and transplantation strategies for delivery to the heart. We will highlight the mechanisms through which hPSC-CMs contribute to heart repair, review major challenges in successful transplantation of hPSC-CMs, and present solutions that are being explored to address these limitations. We end with a discussion of the clinical use of hPSC-CMs, including hurdles to clinical translation, current clinical trials, and future perspectives on hPSC-CM transplantation.
Cardiovascular disease (CVD) is the leading cause of death worldwide. In the United States alone, CVD is responsible for ~655,000 deaths and contributes to $200 billion in spending each year. CVD can lead to myocardial infarction (MI), also known as a “heart attack,” which results in restricted blood flow and extensive cell death within the infarct zone. Due to the limited regenerative capacity of the human heart, infarcted myocardium is replaced by fibrotic scar tissue with inferior contractile performance. Over time, pathological remodeling leads to ventricular wall thinning, which can progress to heart failure. There is currently no treatment available that can restore lost cardiomyocytes after MI, and conventional therapies typically only manage the symptoms (3, 4).
Frogs briefly treated with a five-drug cocktail administered by a wearable bioreactor on the stump were able to regrow a functional, nearly complete limb.
For millions of patients who have lost limbs for reasons ranging from diabetes to trauma, the possibility of regaining function through natural regeneration remains out of reach. Regrowth of legs and arms remains the province of salamanders and superheroes.
But in a study published in the journal Science Advances, scientists at Tufts University and Harvard University’s Wyss Institute have brought us a step closer to the goal of regenerative medicine.
A team mapping radio waves in the Universe has discovered something unusual that releases a giant burst of energy three times an hour, and it’s unlike anything astronomers have seen before. The team who discovered it think it could be a neutron star or a white dwarf—collapsed cores of stars—wi…
Electric bicycle sales have been on a skyward trajectory since early in the pandemic, and new numbers show they are selling more units than electric cars and plug-in hybrids combined. Those figures recently released by the Light Electric Vehicle Association trade group help bolster the case for personal electric vehicles as alternatives to larger cars […].
Electric bicycle sales have been on a skyward trajectory since early in the pandemic, and new numbers show they are selling more units than electric cars and plug-in hybrids combined.
Those figures recently released by the Light Electric Vehicle Association trade group help bolster the case for personal electric vehicles as alternatives to larger cars and trucks.
According to data released by the LEVA, the US saw nearly 790,000 electric bike imports in 2021. That marks a 70% increase from the 463,000 imports in 2020.
